Target intelligence / Profile preview

Respiratory syncytial virus small hydrophobic protein (SH protein)

Target
SH protein
Molecular classification
Viroporin (viral ion channel protein), Small membrane protein
01

Overview

The Respiratory syncytial virus small hydrophobic protein (SH protein) is a short, type II transmembrane protein (64 amino acids) encoded by the RSV genome. The protein oligomerizes into pentamers and forms pH-dependent, acid-activated ion channels (viroporin activity) in host cell membranes, specifically displaying proton and monovalent cation flux. SH protein suppresses apoptosis via inhibition of TNF-α signaling, contributes to immune evasion and RSV pathogenesis, and modulates host cytokine responses such as IL-1β through inflammasome activation. Its absence does not block virus replication or syncytium formation in vitro, but leads to attenuated viral phenotype and diminished pathogenicity in vivo, including reduced lung viral titers and enhanced immune activation. SH accumulates at the Golgi apparatus in infected cells and may facilitate virus release by modifying the secretory pathway. The SH protein is a validated antiviral drug target, with small-molecule inhibitors able to block its channel activity.

Other names
SH proteinRSV SHHuman respiratory syncytial virus SH proteinSmall hydrophobic protein of RSV
02

Mechanism of action

Inhibitors such as pyronin B block SH-mediated ion channel activity in viral and host membranes.

03

Biological functions

Forms pH-dependent ion channels in host membranesInhibits host cell apoptosisModulates cytokine/immune signaling pathways (e.g., inhibition of TNF-α and modulation of IL-1β)Enhances membrane permeability
04

Disease associations

Infection (specifically RSV)Contributes to RSV pathogenesisAttenuated virus phenotype when SH is deleted
05

Safety considerations

No direct safety concerns for targeting SH protein have been published, but SH’s involvement in immune signaling (e.g., modulation of TNF-α and IL-1β) suggests potential for immune-related effects when modulated therapeuticallyMore challenges relate to lack of clinical validation
06

Interacting drugs

Pyronin B

Beyond the preview

Go deeper on Respiratory syncytial virus small hydrophobic protein (SH protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiratory syncytial virus small hydrophobic protein (SH protein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call